Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marinus Pharmaceuticals has received a new US patent no. 7,858,609 from the US Patent and Trademark Office (USPTO) for Ganaxolone, a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolone.
Subscribe to our email newsletter
The new patent entitled, ‘Solid Ganaxolone formulations and methods for the making and use thereof,’ describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of Ganaxolone and will provide coverage until the end of 2026.
Ganaxolone is being developed as a first in class treatment in epilepsy, posttraumatic stress disorder (PTSD) and Fragile-X syndrome (FXS).
Marinus Pharma R&D senior vice president Kenneth Shaw said neurosteroids like Ganaxolone have been difficult to formulate in the past because of differences in exposure that are dependent on the dose and amount of food in the stomach.
"Marinus’ discovery of a novel class of stabilizing agents has produced new nanoparticulate formulations of ganaxolone that appear to be superior to historical formulations in minimizing these differences," Shaw said.